407 related articles for article (PubMed ID: 34904871)
1. Joint MRI T1 Unenhancing and Contrast-enhancing Multiple Sclerosis Lesion Segmentation with Deep Learning in OPERA Trials.
Krishnan AP; Song Z; Clayton D; Gaetano L; Jia X; de Crespigny A; Bengtsson T; Carano RAD
Radiology; 2022 Mar; 302(3):662-673. PubMed ID: 34904871
[TBL] [Abstract][Full Text] [Related]
2. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL; Bar-Or A; Comi G; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Montalban X; Rammohan KW; Selmaj K; Traboulsee A; Wolinsky JS; Arnold DL; Klingelschmitt G; Masterman D; Fontoura P; Belachew S; Chin P; Mairon N; Garren H; Kappos L;
N Engl J Med; 2017 Jan; 376(3):221-234. PubMed ID: 28002679
[TBL] [Abstract][Full Text] [Related]
3. Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis.
Hauser SL; Bar-Or A; Weber MS; Kletzl H; Günther A; Manfrini M; Model F; Mercier F; Petry C; Wing Q; Koendgen H; Smith T; Kappos L
Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36792367
[TBL] [Abstract][Full Text] [Related]
4. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis.
Barkhof F; Kappos L; Wolinsky JS; Li DKB; Bar-Or A; Hartung HP; Belachew S; Han J; Julian L; Sauter A; Napieralski J; Koendgen H; Hauser SL
Neurology; 2019 Nov; 93(19):e1778-e1786. PubMed ID: 31484710
[TBL] [Abstract][Full Text] [Related]
5. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.
Mayer L; Kappos L; Racke MK; Rammohan K; Traboulsee A; Hauser SL; Julian L; Köndgen H; Li C; Napieralski J; Zheng H; Wolinsky JS
Mult Scler Relat Disord; 2019 May; 30():236-243. PubMed ID: 30844611
[TBL] [Abstract][Full Text] [Related]
6. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis.
Turner B; Cree BAC; Kappos L; Montalban X; Papeix C; Wolinsky JS; Buffels R; Fiore D; Garren H; Han J; Hauser SL
J Neurol; 2019 May; 266(5):1182-1193. PubMed ID: 30820738
[TBL] [Abstract][Full Text] [Related]
7. Deep learning segmentation of gadolinium-enhancing lesions in multiple sclerosis.
Coronado I; Gabr RE; Narayana PA
Mult Scler; 2021 Apr; 27(4):519-527. PubMed ID: 32442043
[TBL] [Abstract][Full Text] [Related]
8. Automatic segmentation of gadolinium-enhancing lesions in multiple sclerosis using deep learning from clinical MRI.
Gaj S; Ontaneda D; Nakamura K
PLoS One; 2021; 16(9):e0255939. PubMed ID: 34469432
[TBL] [Abstract][Full Text] [Related]
9. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.
Kappos L; Wolinsky JS; Giovannoni G; Arnold DL; Wang Q; Bernasconi C; Model F; Koendgen H; Manfrini M; Belachew S; Hauser SL
JAMA Neurol; 2020 Sep; 77(9):1132-1140. PubMed ID: 32511687
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies.
Cree BAC; Pradhan A; Pei J; Williams MJ;
Mult Scler Relat Disord; 2021 Jul; 52():103010. PubMed ID: 34147885
[TBL] [Abstract][Full Text] [Related]
11. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
Kappos L; Li D; Calabresi PA; O'Connor P; Bar-Or A; Barkhof F; Yin M; Leppert D; Glanzman R; Tinbergen J; Hauser SL
Lancet; 2011 Nov; 378(9805):1779-87. PubMed ID: 22047971
[TBL] [Abstract][Full Text] [Related]
12. Are multi-contrast magnetic resonance images necessary for segmenting multiple sclerosis brains? A large cohort study based on deep learning.
Narayana PA; Coronado I; Sujit SJ; Sun X; Wolinsky JS; Gabr RE
Magn Reson Imaging; 2020 Jan; 65():8-14. PubMed ID: 31670238
[TBL] [Abstract][Full Text] [Related]
13. Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension.
Hauser SL; Kappos L; Arnold DL; Bar-Or A; Brochet B; Naismith RT; Traboulsee A; Wolinsky JS; Belachew S; Koendgen H; Levesque V; Manfrini M; Model F; Hubeaux S; Mehta L; Montalban X
Neurology; 2020 Sep; 95(13):e1854-e1867. PubMed ID: 32690791
[TBL] [Abstract][Full Text] [Related]
14. Deep Learning for Predicting Enhancing Lesions in Multiple Sclerosis from Noncontrast MRI.
Narayana PA; Coronado I; Sujit SJ; Wolinsky JS; Lublin FD; Gabr RE
Radiology; 2020 Feb; 294(2):398-404. PubMed ID: 31845845
[TBL] [Abstract][Full Text] [Related]
15. Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort study.
Jayachandran Preetha C; Meredig H; Brugnara G; Mahmutoglu MA; Foltyn M; Isensee F; Kessler T; Pflüger I; Schell M; Neuberger U; Petersen J; Wick A; Heiland S; Debus J; Platten M; Idbaih A; Brandes AA; Winkler F; van den Bent MJ; Nabors B; Stupp R; Maier-Hein KH; Gorlia T; Tonn JC; Weller M; Wick W; Bendszus M; Vollmuth P
Lancet Digit Health; 2021 Dec; 3(12):e784-e794. PubMed ID: 34688602
[TBL] [Abstract][Full Text] [Related]
16. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis.
Elliott C; Belachew S; Wolinsky JS; Hauser SL; Kappos L; Barkhof F; Bernasconi C; Fecker J; Model F; Wei W; Arnold DL
Brain; 2019 Sep; 142(9):2787-2799. PubMed ID: 31497864
[TBL] [Abstract][Full Text] [Related]
17. Automated Meningioma Segmentation in Multiparametric MRI : Comparable Effectiveness of a Deep Learning Model and Manual Segmentation.
Laukamp KR; Pennig L; Thiele F; Reimer R; Görtz L; Shakirin G; Zopfs D; Timmer M; Perkuhn M; Borggrefe J
Clin Neuroradiol; 2021 Jun; 31(2):357-366. PubMed ID: 32060575
[TBL] [Abstract][Full Text] [Related]
18. Deep-Learning-Based Neural Tissue Segmentation of MRI in Multiple Sclerosis: Effect of Training Set Size.
Narayana PA; Coronado I; Sujit SJ; Wolinsky JS; Lublin FD; Gabr RE
J Magn Reson Imaging; 2020 May; 51(5):1487-1496. PubMed ID: 31625650
[TBL] [Abstract][Full Text] [Related]
19. LST-AI: A deep learning ensemble for accurate MS lesion segmentation.
Wiltgen T; McGinnis J; Schlaeger S; Kofler F; Voon C; Berthele A; Bischl D; Grundl L; Will N; Metz M; Schinz D; Sepp D; Prucker P; Schmitz-Koep B; Zimmer C; Menze B; Rueckert D; Hemmer B; Kirschke J; Mühlau M; Wiestler B
Neuroimage Clin; 2024; 42():103611. PubMed ID: 38703470
[TBL] [Abstract][Full Text] [Related]
20. Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials.
Giovannoni G; Kappos L; de Seze J; Hauser SL; Overell J; Koendgen H; Manfrini M; Wang Q; Wolinsky JS
Eur J Neurol; 2022 Apr; 29(4):1238-1242. PubMed ID: 33724637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
